

Table 1: Indications

FDA indication	Gemifloxacin	Levofloxacin	Gatifloxacin
Acute bacterial sinusitis	Not approved	<i>S. pneumoniae</i> <i>H. influenzae</i> <i>M. catarrhalis</i>	<i>S. pneumoniae</i> <i>H. influenzae</i>
Acute bacterial exacerbation of chronic bronchitis (ABECB)	<i>S. pneumoniae</i> <i>H. influenzae</i> <i>H. parainfluenzae</i> <i>M. catarrhalis</i>	<i>S. aureus</i> <i>S. pneumoniae</i> <i>H. influenzae</i> <i>H. parainfluenzae</i> <i>M. catarrhalis</i>	<i>S. pneumoniae</i> <i>H. influenzae</i> <i>H. parainfluenzae</i> <i>M. catarrhalis</i> <i>S. aureus</i>
Community-acquired pneumonia (CAP)	<i>S. pneumoniae</i> (including penicillin-resistant strains, MIC > 2 mg/L) <i>H. influenzae</i> <i>M. catarrhalis</i> <i>M. pneumoniae</i> <i>C. pneumoniae</i> <i>K. pneumoniae</i>	<i>S. aureus</i> <i>S. pneumoniae</i> (including penicillin-resistant strains, MIC > 2 mg/L) <i>H. influenzae</i> <i>H. parainfluenzae</i> <i>K. pneumoniae</i> <i>M. catarrhalis</i> <i>C. pneumoniae</i> <i>L. pneumoniae</i> <i>M. pneumoniae</i>	<i>S. pneumoniae</i> (including penicillin-resistant strains, MIC > 2 mg/L) <i>H. influenzae</i> <i>H. parainfluenzae</i> <i>M. catarrhalis</i> <i>S. aureus</i> <i>M. pneumoniae</i> <i>C. pneumoniae</i> <i>L. pneumoniae</i>
Skin and skin structure infections	Not approved	<i>S. aureus</i> * <i>E. faecalis</i> <i>S. pyrogens</i> * <i>Proteus mirabilis</i>	Not approved
Urinary tract infections	Not approved	<i>E. faecalis</i> <i>E. cloacae</i> <i>E. coli</i> * <i>K. pneumoniae</i> * <i>Proteus mirabilis</i> <i>P. Aeruginosa</i> <i>S. saprophyticus</i>	<i>E. coli</i> * <i>K. Pneumoniae</i> * <i>Proteus mirabilis</i> *
Acute pyelonephritis	Not approved	<i>E. coli</i>	<i>E. coli</i>
Gynecologic and pelvic infections	Not approved	Not approved	<i>N. gonorrhoeae</i>

* Approved in complicated and uncomplicated infection